Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rohit Loomba

Showing results (541-550 of 636) with videos related to

Pageof 64
Sort By:
Gastroenterology|July 26, 2021
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a TrialRohit Loomba, Rizwana Mohseni, K Jean Lucas, et al.
Hepatology (Baltimore, Md.)|July 19, 2024
Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: Systematic review and network meta-analysisBenjamin Koh, Jieling Xiao, Cheng Han Ng, et al.
Alimentary Pharmacology & Therapeutics|September 6, 2024
MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controlsDaniela S Allende, Oscar Cummings, Alice L Sternberg, et al.
Pediatric Cardiology|June 25, 2022
Pulmonary Atresia with Intact Ventricular Septum: Midterm Outcomes from a Multicenter CohortIlias Iliopoulos, Christopher W Mastropietro, Saul Flores, et al.
Alimentary Pharmacology & Therapeutics|February 2, 2024
Meta-analysis: Prevalence and impact of alcohol abstinence in alcohol-associated cirrhosisWen Hui Lim, Phoebe Tay, Cheng Han Ng, et al.
Journal of Hepatology|December 17, 2022
Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver diseaseArun J Sanyal, Stephen A Williams, Joel E Lavine, et al.
Cell Metabolism|May 4, 2017
Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver DiseaseRohit Loomba, Victor Seguritan, Weizhong Li, et al.
Alimentary Pharmacology & Therapeutics|September 11, 2023
The silent burden of non-alcoholic fatty liver disease in the elderly: A global burden of disease analysisPojsakorn Danpanichkul, Cheng Han Ng, Mark D Muthiah, et al.
Hepatology Communications|June 19, 2024
AMPED study: Protocol for a randomized controlled trial of different doses of aerobic exercise trainingJonathan G Stine, Breianna Hummer, Nataliya Smith, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 23, 2023
Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b StudyManal F Abdelmalek, Arun J Sanyal, Atsushi Nakajima, et al.
Pageof 64

Showing results (541-550 of 636) with videos related to

Sort By:
Pageof 64
Gastroenterology|July 26, 2021
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a TrialRohit Loomba, Rizwana Mohseni, K Jean Lucas, et al.
Hepatology (Baltimore, Md.)|July 19, 2024
Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: Systematic review and network meta-analysisBenjamin Koh, Jieling Xiao, Cheng Han Ng, et al.
Alimentary Pharmacology & Therapeutics|September 6, 2024
MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controlsDaniela S Allende, Oscar Cummings, Alice L Sternberg, et al.
Pediatric Cardiology|June 25, 2022
Pulmonary Atresia with Intact Ventricular Septum: Midterm Outcomes from a Multicenter CohortIlias Iliopoulos, Christopher W Mastropietro, Saul Flores, et al.
Alimentary Pharmacology & Therapeutics|February 2, 2024
Meta-analysis: Prevalence and impact of alcohol abstinence in alcohol-associated cirrhosisWen Hui Lim, Phoebe Tay, Cheng Han Ng, et al.
Journal of Hepatology|December 17, 2022
Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver diseaseArun J Sanyal, Stephen A Williams, Joel E Lavine, et al.
Cell Metabolism|May 4, 2017
Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver DiseaseRohit Loomba, Victor Seguritan, Weizhong Li, et al.
Alimentary Pharmacology & Therapeutics|September 11, 2023
The silent burden of non-alcoholic fatty liver disease in the elderly: A global burden of disease analysisPojsakorn Danpanichkul, Cheng Han Ng, Mark D Muthiah, et al.
Hepatology Communications|June 19, 2024
AMPED study: Protocol for a randomized controlled trial of different doses of aerobic exercise trainingJonathan G Stine, Breianna Hummer, Nataliya Smith, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 23, 2023
Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b StudyManal F Abdelmalek, Arun J Sanyal, Atsushi Nakajima, et al.
Pageof 64